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data are unavailable or insufﬁ cient, indirect comparison is increasingly used across 
therapy areas, reﬂ ected by recent NICE guidance. To maximise quality of submissions, 
analyses must use validated methodology, manage heterogeneity appropriately and
clearly justify decisions and usage of methods and comparators. Rationale for use of 
indirect comparisons is also required.
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OBJECTIVES: To explore key decision-makers’ agreement on desirable scenarios to
effectively implement health technologies in the public sector in the future. From 2006 
onwards, the Spanish government has undertaken several initiatives to establish a 
reliable mechanism for implementing technologies in the National Health System 
(NHS). METHODS: A naturalistic, qualitative, two phases study was conducted. The 
current situation of implementing health technologies’ in Spain was explored on an 
earlier study. Based on the present circumstances, both phases of this study sought to 
explore and determine the level of agreement amongst key decision- makers on suitable 
strategies to improve the existing conditions. Phase One: semi-structured interviews
explored their views on desirable scenarios to more effectively implement health
technologies in the public sector. Phase Two: the Delphi method determined the level
of agreement amongst participants on key messages consistently endorsed during the
interviews. Two rounds of questionnaires were required to consolidate consensus level.
RESULTS: A total of 35 interviews were conducted, including managers, researchers 
and evaluators across country. Several categories of information emerged and were 
assessed in the Delphi process amongst 26 participants. Most responses (q75%) agreed
on: 1) decision making: based on a demonstrated incremental cost-beneﬁ t ratio; 2) 
desirable attributes: efﬁ ciency and cost-beneﬁ t, safety and eﬁ cacy; 3) uniﬁ ed processes 
countrywide; 4) information: open and consistent management across, and within,
levels of decision, with the health technology evaluation agencies (HTEA), and the 
industry; 5) education: continued training of decision- makers; 6) evaluation model: 
organized HTEA, coordinating efforts, following up transparent, participative and
methodologically robust processes agreed across Europe; 7) ﬁ nancing mechanisms: 
more ﬂ exible, collaborative formulas to avoid blocking the implementation of cost-
beneﬁ cial technologies; and 8) the industry’s role: expert, legitimate provider, “trainer 
of trainees” CONCLUSIONS: These ﬁ ndings should serve the Spanish Health Author-
ities to effectively improve the implementation of health technologies in the NHS.
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OBJECTIVES: Reasons provided by the health technology appraisal (HTA) agencies 
for the guidance issued vary across the board. Following interest from a previous 
ISPOR presentation, we sought to further investigate the reasons for recommenda-
tion/rejection between NICE, SMC, CADTH, and PBAC with a speciﬁ c focus on
disease-speciﬁ c reasons. METHODS: A previously developed database was updated 
with data from submissions appraised between 31 May and 31 December 2008 by 
NICE, SMC, CADTH, and PBAC, in England/Wales, Scotland, Canada, and Australia,
respectively. Submissions with opposing decision outcomes were included and were
categorised by disease based on the BNF (cardiovascular system, CNS, endocrine
system, gastro-intestinal system, infections, malignant diseases and immunosuppres-
sion, musculoskeletal and joint diseases, nutrition and blood, obstetrics, gynaecology, 
and urinary tract disorders, respiratory system, and skin). Reasons for acceptance/
rejection were analysed across the disease categories. RESULTS: In total, 83 submis-
sions were included for analysis. Across all HTAs, the most common rejection reasons 
for skin disease interventions included “not more effective than comparators” and 
“not cost-effective”; these reasons were demonstrated in 100% of the submissions for
interventions relating to skin disorders. The most common rejection reasons in malig-
nant diseases and immunosuppression included “not cost-effective” and “concerns
over the economic model” (100% for both). The majority of the reasons for rejection
were reported in 50% or less of the submissions per disease group. Of the recom-
mended interventions, those for the treatment of skin disease were all “more effective
than placebo and comparators” as well as having a lower cost. Interventions for 
infectious diseases and obstetrics, gynaecology, and urinary tract disorders demon-
strated a wide range of reasons for rejection. CONCLUSIONS: Sub-group analysis 
categorised by disease provides further insight into the primary reasons for rejection 
and recommendation across HTA bodies. Analysing trends within these submissions
highlights potential obstacles for new interventions within a speciﬁ c disease area.
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REVIEW OF HTA RECOMMENDATIONS FOR DRUG THERAPIES IN 
POLAND ISSUED FROM SEPTEMBER 6, 2007 UNTIL OCTOBER 28, 
2008 BY THE CONSULTATIVE COUNCIL (APPRAISAL COMMITTEE) 
OF AHTAPOL IN POLAND
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OBJECTIVES: Review of HTA recommendations issued by the Consultative Council 
of AHTAPol in Poland. METHODS: Fifty-nine drug recommendations, January 
2007–58/16/2008, from September 2007 until October 2008, available online, were 
analyzed. Appraisals were grouped into positive and negative recommendations. The 
clinical and non-clinical reasons for rejection of use were studied. The positive guid-
ances were divided into recommendations with major, minor and without restrictions. 
RESULTS: Thirty-two HTA reports received negative recommendations; 26 on the 
grounds of clinical evidence and 6 because of non-clinical issues. Among 26 recom-
mendations, insufﬁ cient clinical effectiveness data was the most frequently stated
reason (18 cases). In other eight guidances, the argument of poor efﬁ cacy or safety 
was raised. Among non-clinical aspects, unacceptable cost-effectiveness ratio was 
given four times. The unacceptable budget impact and risk of off-label use were men-
tioned each one only once. Twenty-seven HTA reports received positive recommenda-
tions, of which 18 for use with major restrictions, 7 with minor restrictions and 2 
without additional restrictions. Among those 18 recommendations, several restrictions
were imposed simultaneously. The most common was prescription restricted to speciﬁ c
subpopulations (15 cases), followed by the need for an improvement of cost-effective-
ness (6 cases), use as second line (5 cases), use if intolerant to other treatment (3 cases), 
reimbursement within speciﬁ c period (2 cases). Among recommendations with minor 
restrictions, lowering price was mentioned ﬁ ve times and use by specialist twice. The 
appraisal of cost-effectiveness analysis was included more frequently in positive rather 
than negative quidances; 63% vs. 57%. The study revealed that an ICER was above 
WHO threshold, accepted by AHTAPoL, in 65% of positive recommendations. An 
ICER was below threshold in 44% of negative recommendations. CONCLUSIONS:
The negative and positive HTA guidances with major restrictions prevailed in Poland. 
Clinical rather than pharmacoeconomic aspects were the most common reason for an 
appraisal recommendation.
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OBJECTIVES: Budget impact analyses (BIAs), along with cost-effectiveness analyses, 
are an essential part of a comprehensive economic assessment of a new health technol-
ogy and increasingly required by national regulatory agencies and managed care
organizations. This study describes the characteristics and growth of BIAs published
in the literature over the past 5–6 years. METHODS: An initial search was conducted
using PubMed, a service of the U.S. National Library of Medicine. Approximately 
800 citations were retrieved using key words of “budget impact” and “budget analy-
sis” and limits of “English Language” and “published within the last 6 years”. Addi-
tional articles were obtained through ancestral and related article searches. All relevant 
BIA articles were identiﬁ ed through an initial title review and secondary abstract
review and included in this study. RESULTS: We identiﬁ ed 32 BIAs published between 
2003 and 2008. The number of studies published each year were 1 (2003), 3 (2004),
5 (2005), 6 (2006), 7 (2007) and 10 (2008), showing a steady upward trend. The
publishing journals had impact factors ranging from 1.985 to 5.888. Just over half of 
published studies (18/32) assessed budget impact of a health technology in the United 
States, while the remaining studies were performed in European countries, Canada 
and Brazil. Although the majority of published BIAs (22/32) examined budget impact
of a speciﬁ c drug, several studies assessed budget impact of various procedures e.g.
surgical, endoscopic. Fourteen (44%) of the published BIAs were performed in
conjunction with a cost-effectiveness analysis. CONCLUSIONS: Despite increased 
demand for and recent growth in number of published BIAs, the absolute number of 
BIA studies published in peer-reviewed journals remains limited. Future studies should
examine whether the quality of published BIAs has improved over time and examine 
changes in practices following the recently published recommendations of the ISPOR
Task Force on good research practices for BIAs.
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OBJECTIVES: The outcomes of health technology assessment (HTA) appraisals con-
ducted by appraising bodies vary greatly and are inﬂ uenced by a range of factors. The 
aim of this research was to determine whether the sequence of agencies in which HTAs
are submitted has an impact on the guidance issued. METHODS: Data from submis-
sions to NICE, SMC and CADTH between 1 November 2005 and 31 December 2008
were included. Only interventions appraised by at least two agencies were of interest.
Extracted information included the name of the intervention, the guidance issued and
the date of guidance. In addition, a correlation between the sequence of submission 
and guidance issued was assessed. RESULTS: A total of 46 interventions were submit-
ted to at least two appraising bodies. In 76% of cases, the ﬁ rst body to conduct
appraisals was the SMC. In contrast, only 4% of the submissions were submitted to
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NICE ﬁ rst. Nineteen of the 46 submissions were appraised by NICE; 10% of the cases
were ﬁ rst assessed by NICE, 60% were appraised by NICE second, and in 30% of 
the cases, NICE were the last in the sequence to appraise. It is interesting to note that 
the rate of acceptance by the SMC was approximately 65% regardless of whether the
intervention was appraised by the SMC or CADTH ﬁ rst. In contrast the acceptance 
rate for CADTH was observed to be much higher when interventions were appraised 
by the SMC ﬁ rst compared to when CADTH conducted the ﬁ rst appraisal; 56% and 
20% respectively. CONCLUSIONS: The SMC have generally received submissions 
before NICE and CADTH. In comparison, NICE were rarely the ﬁ rst to appraise an
intervention. Reviewing the sequence in which submissions are appraised by each of 
these bodies and the inﬂ uence of this on the guidance issued may inform future stra-
tegic planning of submissions.
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OBJECTIVES: Health technology assessment (HTA) is the process used to evaluate
emerging and existing technologies (e.g., pharmaceuticals, medical devices, and diag-
nostics), and to determine how these technologies will impact health care service
delivery and society. Despite the growing importance of HTA as a decision tool to 
govern the adoption process for emerging technologies, a systematic and hierarchical 
approach to characterize the decision-making process used by various countries has 
not been developed. The objective of this study was to model the decision pathway
that describes the underlying decision-making structure and process for HTA in eight 
selected countries. METHODS: Members of the International Society for Pharmaco-
economics and Outcomes Research Special Interest Group for HTA performed 
research online to identify resources that described health systems and decision path-
ways for the following countries: Australia, Canada, France, Germany, Spain, Sweden, 
UK, and the United States. Once proposed decision structures were reviewed by com-
mittee members familiar with that country, decision models were developed for each 
country and validated for clarity and accuracy. RESULTS: The HTA decision-making 
hierarchy developed for each country identiﬁ ed the decision maker as the payer (i.e., 
person or organization) who makes the ﬁ nal decision for coverage and payment for 
an approved technology. The evaluator was deﬁ ned as a person or organization that 
provides input into the decision-making process via HTA development, but did not 
make the ﬁ nal decision for coverage and payment. The decision-making process
referred to the HTA evaluation process, as deﬁ ned in the public domain, for emerging 
technologies in consideration for coverage and payment. CONCLUSIONS: Each of 
the countries examined utilized a unique decision-making structure and maintained
detailed processes for HTA input to the ﬁ nal decision maker. Decision pathways for
HTA in the countries examined continue to evolve in response to societal needs for 
emerging technologies.
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OBJECTIVES: Health technology assessment (HTA) started in the United States (US)
to quantify the beneﬁ ts, harms and costs associated with new technologies. Paralleling 
methodological advances, applied HTA processes were instituted in many countries
to inform decisions about adopting new technologies. Within the context of discus-
sions regarding a new center for comparative effectiveness in the US, we compared
HTA of medications in six jurisdictions: Australia, Canada, England and Wales, the
Netherlands, Scotland and Sweden. The objective was to identify characteristics
of HTA processes and agencies that may inform the structure and operation of a
US center for comparative effectiveness. METHODS: We identiﬁ ed characteristics
of each health care system and HTA processes, including: the medications reimburse-
ment processes; whether recommendations are mandatory; and structure and transpar-
ency of the process using the accountability for reasonableness framework. RESULTS:
For Australia, England and Wales and the Netherlands, reimbursement decisions
are made nationally, while in Canada, Scotland, and Sweden, formularies are main-
tained regionally. HTA processes range from manufacturer-prepared single product 
submissions to comprehensive assessments based on de novo analyses. While six 
jurisdictions have quasi-governmental HTA agencies, the Netherlands relies largely on 
a reference-pricing system. Sweden has two HTA agencies: one for rapid assessment
of single medications and another which undertakes multiple-technology assessments 
involving other funding silos. Scotland, and to lesser extents England and Wales 
and Sweden, have implemented transparent processes, e.g., by posting meeting
minutes and the reasoning for recommendations. CONCLUSIONS: The US health 
care system is fragmented and characterized by insured populations with different
health needs. Characteristics directly relevant to a US centre include having: non-
mandatory recommendations; and transparent two-tiered processes. Collecting better
evidence on real-world treatment effects – as is being done in some jurisdictions – 
would increase the number and types of stakeholders who could apply the information 
for decision-making.
HEALTH CARE USE & POLICY STUDIES – Prescribing Behavior &
Treatment Guidelines
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OBJECTIVES: To assess the impact electronic prescribing system the use of an has on 
a provider’s prescribing of low cost generic drugs through lower costing channels. 
METHODS: Generic/brand, mail/retail, and cost-per-day (costs) for over nine million
adjudicated prescriptions dispensed between July 2002 and December 2005 were 
incorporated into independent multivariate logistic and general linear models to 
compare prescriptions from 468 providers prescribed before and after using an elec-
tronic prescribing system and 28,734 “no use” (control) providers. Separate models 
for ACE Inhibitors, ARB and ARB Combinations, H2 Antagonists, HMG Inhibitors, 
NSAIDs, PPIs, and SSRIs classes included independent variables for: provider degree, 
specialty, and electronic prescribing system use (no, little and regular use prescribed
50 prescriptions/month); patient sex, age (continuous), and regimen status; claim 
month and distribution channel (except in mail/retail models). Signiﬁ cance was a 
p-value a0.01. RESULTS: Generic and mail prescriptions were generally more likely 
to be prescribed from providers with regular use (ORs: 0.80pC1.20) and less likely
from those with little or no use (ORs: 0.65pC1.23) than prescriptions from the pre-
period of providers who became regular users (OR  1.00), with most signiﬁ cant and 
few exceptions. Costs were generally lower for providers with regular use (CEs: 
$0.33pC$0.04) and higher for providers with little or no use (CEs: $0.13pC$0.14) 
than prescriptions from the pre-period of providers who became regular users (CE 
$0.00), with some signiﬁ cant and some exceptions. CONCLUSIONS: Similar underly-
ing patterns found across multiple classes provide support for linking regular use of 
electronic prescribing systems to providers being even more likely to prescribe generics 
drugs and having them dispensed through mail, both of which likely lower overall 
costs. Additional research should be performed to better assess the robustness of these 
ﬁ nding as participation expands and in more therapeutic classes.
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OBJECTIVES: To determine whether the implementation of Medicare Part D coverage 
affected trends in average per physician prescription volume of select drugs in the six
classes deemed by CMS/Medicare Part D to be medically necessary for reimbursement.
To assess these trends over the 2005–2008 period, including the January 1, 2006 
implementation of Medicare Part D. To investigate whether prescribers of different 
specialties were affected to a greater of lesser extent than their peers. METHODS: For 
each of the six protected classes deﬁ ned by CMS (Antineoplastics, Antidepressants, 
Anticonvulsants, Immunosuppressants, Antipsychotics, Antiretrovirals) a comparative 
market basket consisting of the top 2 prescribed anticonvulsants (clonazepam, gaba-
pentin), antidepressants (escitaprolam, ﬂ uoxetine), antipsychotics (quetiapine, risperi-
done), HIV/AIDS (emtricitabine/tenofovir, ritonavir) and immunosuppressants 
(azathioprine, mycophenolate) were selected based on total prescriptions (TRx) 
between January 2005 and June 2008. For that time frame, average prescription 
volume, by individual physician, were collected monthly using SDI/ Verispan’s VONA 
and VOPA databases. RESULTS: Of 103 physician specialty/molecule prescribing 
pairs, average monthly prescription volume for the 12 month period after implementa-
tion of Medicare Part D (January 2006 – December 2006) coverage increased signiﬁ -
cantly (p  0.05) versus the prior 12 months (January 2005-December 2005 for 79% 
(34/43) of combinations examined, and conversely, a signiﬁ cant (p  0.05) decrease 
was observed for 80% (48/60) combinations. CONCLUSIONS: The introduction of 
Medicare Part D had signiﬁ cant impact on utilization for the majority of high volume 
drugs in the Medicare Part D designated protected classes. A possible explanation is
that the reorganization of formulary structures and tier placement for many of these 
drugs led to pricing changes for patients, which in turn were observed by physicians 
and led to subtle but signiﬁ cant changes in prescribing behavior. In addition to changes
for specialty physicians, signiﬁ cant changes in volume were also noted for GP/FP/IM
physicians. Ongoing investigation into drug pricing and tier placement may lead to 
greater clarity.
